Study Objectives: There remains an important and unmet need for fully effective and acceptable treatments in obstructive sleep apnea (OSA). At present, there are no approved drug treatments. Dronabinol has shown promise for OSA pharmacotherapy in a small dose-escalation pilot study. Here, we present initial findings of the Phase II PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial, a fully blinded parallel groups, placebo-controlled randomized trial of dronabinol in people with moderate or severe OSA.
Methods: By random assignment, 73 adults with moderate or severe OSA received either placebo (N = 25), 2.5 mg dronabinol (N = 21), or 10 mg dronabinol (N = 27) daily, 1 hour before bedtime for up to 6 weeks.
Results: At baseline, overall apnea-hypopnea index (AHI) was 25.9 ± 11.3, Epworth Sleepiness Scale (ESS) score was 11.45 ± 3.8, maintenance of wakefulness test (MWT) mean latency was 19.2 ± 11.8 minutes, body mass index was 33.4 ± 5.4 kg/m2, and age was 53.6 ± 9.0 years. The number and severity of adverse events, and treatment adherence (0.3 ± 0.6 missed doses/week) were equivalent among all treatment groups. Participants receiving 10 mg/day of dronabinol expressed the highest overall satisfaction with treatment (p = .04). In comparison to placebo, dronabinol dose-dependently reduced AHI by 10.7 ± 4.4 (p = .02) and 12.9 ± 4.3 (p = .003) events/hour at doses of 2.5 and 10 mg/day, respectively. Dronabinol at 10 mg/day reduced ESS score by -3.8 ± 0.8 points from baseline (p < .0001) and by -2.3 ± 1.2 points in comparison to placebo (p = .05). MWT sleep latencies, gross sleep architecture, and overnight oxygenation parameters were unchanged from baseline in any treatment group.
Conclusions: These findings support the therapeutic potential of cannabinoids in people with OSA. In comparison to placebo, dronabinol was associated with lower AHI, improved self-reported sleepiness, and greater overall treatment satisfaction. Larger scale clinical trials will be necessary to clarify the best potential approach(es) to cannabinoid therapy in OSA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806568 | PMC |
| http://dx.doi.org/10.1093/sleep/zsx184 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Cannabis is increasingly used and debates about the legalisation of the recreational use of cannabis are ongoing. In this prospective, placebo-controlled study in healthy volunteers not regularly consuming cannabis, subjective psychotropic and somatic effects after a single dose of intravenous THC were assessed and quantified over 48 h.
Methods: Twenty-five healthy volunteers received a single IV bolus of THC and 6 received normal saline.
A randomised dose finding study of combination dronabinol and acetazolamide for the treatment of obstructive sleep apnoea.
Sleep
November 2024
Epilepsy and Neuropharmacology Clinical Trials Unit, Alfred Brain, Alfred Health, Melbourne, Victoria, Australia.
Article Synopsis
- This study explores a new treatment combining acetazolamide and dronabinol (IHL-42X) for obstructive sleep apnea (OSA) in patients who don't respond to current therapies.
- Participants with moderate to severe OSA underwent a crossover trial of different IHL-42X doses and a placebo to assess changes in apnea severity and related metrics.
- The results showed significant reductions in apnea severity with IHL-42X compared to placebo, particularly at medium dose levels, while no serious adverse effects were reported, indicating it's a safe alternative.
LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder.
PLoS One
September 2024
Psychology and Neuroscience, University of Colorado Boulder, Boulder, CO, United States of America.
Background: As cannabis legalization continues to spread across the United States, average Δ9-tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce cannabis use among high potency cannabis users. Some research has found that the non-intoxicating cannabinoid cannabidiol reduces cannabis use and cannabis use disorder-related symptoms, such as affective disturbance and withdrawal. Results of these studies are promising but limited to synthetic or isolated forms of cannabidiol.
View Article and Find Full Text PDFMulti-modal and bi-directional effects of a synthetic Δ9-Tetrahydrocannabinol (THC) analogue, Nabilone, on spatio-temporal binding windows: Evidence from the projected hand illusion.
PLoS One
September 2024
Pharmacology, School of Biomedical Sciences, The University of Western Australia, Perth, WA, Australia.
Abnormally widened spatial and temporal binding windows (SBW/TBWs; length of space/time whereby stimuli are considered part of the same percept) are observed in schizophrenia. TBW alterations have been associated with altered sense of agency (hereafter referred to as agency), and an associative relationship between embodiment (body ownership) and agency has been proposed. SBWs/TBWs are investigated separately, but no evidence exists of these being separate in mechanism, system or function.
View Article and Find Full Text PDFOral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial.
J Clin Oncol
December 2024
NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Article Synopsis
- This clinical trial tested the effectiveness of an oral cannabis extract (THC:CBD) on adults experiencing severe nausea and vomiting from chemotherapy, despite using standard anti-nausea medications.
- The results showed that the cannabis extract significantly increased the rate of complete responses (no vomiting or need for rescue meds) from 8% to 24% compared to a placebo.
- While participants reported some mild side effects like sedation and dizziness, there were no serious adverse events linked to the cannabis treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!